

# UCLA

## UCLA Previously Published Works

### Title

Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a).

### Permalink

<https://escholarship.org/uc/item/1rm4q7xq>

### Authors

Razavi, Alexander  
Richardson, LaTonia  
Coronado, Fátima  
et al.


### Publication Date

2024-06-01

### DOI

10.1016/j.ajpc.2024.100674

Peer reviewed



## Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

Alexander C. Razavi<sup>a</sup>, LaTonia C. Richardson<sup>b</sup>, Fátima Coronado<sup>b</sup>, Omar Dzaye<sup>c</sup>, Harpreet S. Bhatia<sup>d</sup>, Anurag Mehta<sup>e</sup>, Arshed A. Quyyumi<sup>a</sup>, Viola Vaccarino<sup>a</sup>, Matthew J. Budoff<sup>f</sup>, Khurram Nasir<sup>g</sup>, Sotirios Tsimikas<sup>d</sup>, Seamus P. Whelton<sup>c</sup>, Michael J. Blaha<sup>c</sup>, Roger S. Blumenthal<sup>c</sup>, Laurence S. Sperling<sup>a,b,\*</sup>

<sup>a</sup> Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, United States

<sup>b</sup> Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States

<sup>c</sup> Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States

<sup>d</sup> Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA, United States

<sup>e</sup> VCU Health Pauley Heart Center and Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, United States

<sup>f</sup> Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, United States

<sup>g</sup> Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, United States

### ARTICLE INFO

#### Keywords:

Lipoprotein(a)  
Aspirin  
Cardiovascular disease  
NHANES

### ABSTRACT

**Objective:** Lipoprotein(a) [Lp(a)] is an atherogenic and prothrombotic lipoprotein associated with atherosclerotic cardiovascular disease (ASCVD). We assessed the association between regular aspirin use and ASCVD mortality among individuals *with* versus *without* elevated Lp(a) in a nationally representative US cohort.

**Methods:** Eligible participants were aged 40–70 years without clinical ASCVD, reported on aspirin use, and had Lp(a) measurements from the Third National Health and Nutrition Examination Survey (NHANES III, 1988–1994), the only cycle of this nationally representative US cohort to measure Lp(a). Regular aspirin use was defined as taking aspirin  $\geq 30$  times in the previous month. Using NHANES III linked mortality records and weighted Cox proportional hazards regression, the association between regular aspirin use and ASCVD mortality was observed in those *with* and *without* elevated Lp(a) ( $\geq 50$  versus  $< 50$  mg/dL) over a median 26-year follow-up.

**Results:** Among 2,990 persons meeting inclusion criteria (~73 million US adults), the mean age was 50 years, 86% were non-Hispanic White, 9% were non-Hispanic Black, 53% were female, and 7% reported regular aspirin use. The median Lp(a) was 14 mg/dL and the proportion with elevated Lp(a) was similar among those *with* versus *without* regular aspirin use (15.1% versus 21.9%,  $p = 0.16$ ). Among individuals with elevated Lp(a), the incidence of ASCVD mortality per 1,000 person-years was lower for those *with* versus *without* regular aspirin use (1.2, 95% CI: 0.1–2.3 versus 3.9, 95% CI: 2.8–4.9). In multivariable modeling, regular aspirin use was associated with a 52% lower risk of ASCVD mortality among individuals with elevated Lp(a) (HR=0.48, 95% CI: 0.28–0.83), but not for those without elevated Lp(a) (HR=1.01, 95% CI: 0.81–1.25;  $p$ -interaction=0.001).

**Conclusion:** Regular aspirin use was associated with significantly lower ASCVD mortality in adults without clinical ASCVD who had elevated Lp(a). These findings may have clinical and public health implications for aspirin utilization in primary prevention.

### 1. Introduction

The 2019 American College of Cardiology/American Heart

Association Guideline on the Primary Prevention of Cardiovascular Disease recommends an individualized approach to prescribing aspirin for individuals aged 40–70 years who are at higher atherosclerotic

\* Corresponding author at: Katz Professor in Preventive Cardiology, Founder, Emory Center for Heart Disease Prevention, 1605 Chantilly Drive NE, Emory Heart and Vascular Center at Executive Park, Atlanta, Georgia, 30324, United States.

E-mail address: [lsperli@emory.edu](mailto:lsperli@emory.edu) (L.S. Sperling).

<https://doi.org/10.1016/j.ajpc.2024.100674>

Received 14 March 2024; Received in revised form 10 April 2024; Accepted 15 April 2024

Available online 27 April 2024

2666-6677/Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Table 1**

Characteristics of United States adults aged 40–70 years without clinical ASCVD with available measures of Lp(a), stratified by aspirin use.

Characteristics	Estimated US Population <sup>a</sup>	Total Number in Current NHANES III Sample	All <sup>c</sup>	Without Regular Aspirin Use <sup>c</sup>	Regular Aspirin Use <sup>c</sup>	P-Value
Total Population	73,047,156	2,990	2,990	2,773	217	–
Age, years, median (Q1, Q3)	–	–	50.2 (43.5, 58.6)	49.8 (43.3, 58.0)	52.4 (44.8, 61.7)	0.006
Female,% (95% CI)	38,788,040	1,676	53.1 (50.7, 55.5)	55.4 (54.6, 56.2)	32.2 (28.9, 35.5)	<0.001
Race/Ethnicity,% (95% CI)						<0.001
Non-Hispanic White / Other <sup>b</sup>	63,039,695	1,357	86.3 (82.8, 89.8)	85.4 (84.8, 86.0)	94.6 (93.1, 96.0)	
Non-Hispanic Black	6,866,433	833	9.4 (6.6, 12.3)	10.1 (9.7, 10.6)	3.1 (1.8, 4.4)	
Mexican American	3,141,028	800	4.3 (2.5, 6.1)	4.5 (4.1, 4.9)	2.4 (2.0, 2.7)	
Post-High School Education,%	31,848,560	852	43.6 (42.1, 45.0)	42.9 (41.2, 44.6)	49.2 (46.4, 52.0)	0.003
Family Hx of MI <50 years old,% (95% CI)	12,052,781	391	16.5 (13.8, 19.2)	16.4 (15.7, 17.2)	17.1 (13.9, 20.3)	0.66
Current Cigarette Smoking,%	17,239,129	754	23.6 (20.5, 26.6)	23.1 (21.4, 24.8)	27.7 (24.5, 30.9)	0.004
Body Mass Index, kg/m <sup>2</sup> , mean (95% CI)	–	–	27.7 (27.3, 28.1)	27.7 (27.5, 27.8)	27.7 (27.3, 28.0)	0.98
Systolic Blood Pressure, mmHg, mean (95% CI)	–	–	125.8 (124.6, 127.0)	125.5 (125.0, 126.0)	128.5 (127.4, 129.6)	0.09
Antihypertensive Medication,% (95% CI)	12,052,781	613	16.5 (14.1, 18.8)	15.9 (14.9, 16.9)	21.4 (20.1, 22.7)	<0.001
Diabetes,% (95% CI)	4,601,971	308	6.3 (4.9, 7.6)	6.2 (5.5, 7.0)	6.7 (6.3, 7.1)	0.13
Total Cholesterol, mg/dL, mean (95% CI)	–	–	214.2 (211.8, 216.6)	213.9 (212.3, 215.5)	216.6 (213.9, 219.2)	0.49
HDL-Cholesterol, mg/dL, mean (95% CI)	–	–	50.0 (48.9, 51.2)	50.1 (49.8, 50.4)	49.4 (48.8, 50.0)	0.62
Triglycerides, mg/dL, median (Q1, Q3)	–	–	127.7 (87.8, 188.8)	126.8 (87.3, 189.9)	131.1 (92.4, 183.6)	0.32
Cholesterol-Lowering Medication,% (95% CI)	3,141,028	127	4.3 (3.0, 5.5)	3.6 (3.3, 4.0)	9.7 (7.4, 12.0)	<0.001
Lp(a), mg/dL, median (Q1, Q3)	–	–	14.0 (3.4, 31.5)	13.5 (3.4, 31.2)	18.6 (4.2, 35.2)	0.16
Lp(a) ≥50 mg/dL	11,468,404	612	15.7 (14.7, 16.6)	15.1 (14.3, 15.8)	21.0 (18.1, 23.9)	0.16
eGFR, mL/min/1.73m <sup>2</sup> , mean (95% CI)	–	–	73.9 (72.7, 75.1)	74.1 (73.7, 74.5)	72.4 (71.9, 72.8)	0.17

Source of Data: National Center for Health Statistics: The Third National Health and Nutrition Examination Survey.

eGFR=estimated glomerular filtration rate; Hx=history; Lp(a)=lipoprotein(a); MI=myocardial infarction.

<sup>a</sup> based on 1990 US Census Counts.<sup>b</sup> also includes persons other than non-Hispanic Black or Mexican American.<sup>c</sup> all values are presented as weighted estimates, except for total population row.

cardiovascular disease (ASCVD) risk [1]. Beyond advanced subclinical atherosclerosis [2], the early identification of individuals who may benefit from aspirin therapy for primary prevention remains challenging. Lipoprotein(a) [Lp(a)] is a prothrombotic lipoprotein causally associated with ASCVD; approximately 1 in 5 individuals have elevated Lp(a) [3]. Emerging evidence suggests that individuals with high-risk Lp(a) genotypes or elevated Lp(a) may benefit from aspirin therapy for primary prevention. [4–6] However, prior data has been limited to young female or older adults, has not consistently included measurements of serum Lp(a), and/or has not included ASCVD mortality as an outcome [4–6]. We sought to assess whether the association between aspirin use and ASCVD mortality differed by Lp(a) level in a nationally representative sample of United States (US) adults.

## 2. Methods


The National Health and Nutrition Examination Survey (NHANES) includes a series of national, stratified, multistage probability surveys to select a representative sample of noninstitutionalized adults living in the US. The Third National Health and Nutrition Examination Survey (NHANES III) was collected in two phases (1988–1991 and 1991–1994) and is the only cycle of this nationally representative cohort to measure Lp(a) [7,8]. For the current analysis (Supplemental Figure 1), eligible participants were 1) aged 40–70 years with available measures of Lp(a), 2) reported on aspirin use, 3) did not report a previous history of

myocardial infarction or stroke, and 4) had available information on covariables and follow-up through National Death Index (NDI) records.

Study protocols for NHANES were approved by the National Center for Health Statistics Ethics Review Board. All adult participants provided signed, informed consent. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines for cohort studies. This activity was conducted consistent with applicable federal law and CDC policy.

The public NHANES III Linked Mortality File, which includes NDI searches through December 31, 2019, provided mortality follow-up data. Using the *International Classification of Diseases, Tenth Revision* codes, ASCVD mortality is defined as when “Diseases of the Heart” (I00–I09, I11, I13, I20–I51) or “Cerebrovascular Diseases” (I60–I69) are the underlying cause of death [9]. Participants who had multiple causes of death due to hypertension or diabetes were not considered within the ASCVD mortality definition.

Lp(a) was measured (mg/dL) among participants in the second phase of NHANES III using an enzyme-linked immunosorbent assay specific for apolipoprotein(a) (Strategic Diagnostics Inc., Newark, DE) [10]. Elevated Lp(a) was defined using a threshold of ≥50 mg/dL [3]. Aspirin use was measured using two questions, “In the past month have you taken any aspirin?” and “How often did you use aspirin during the past month?” Participants qualified for regular aspirin use if they reported taking aspirin ≥30 times in the month before the interview. To account for possible every other day dosing regimens, secondary analyses



**Fig. 1.** Cumulative probability of ASCVD mortality according to aspirin use, stratified by normal (A) versus elevated Lp(a) (B).

\*Among individuals with elevated Lp(a), those reporting regular aspirin use had a significantly lower crude cumulative probability of ASCVD mortality.

defined regular aspirin use as taking aspirin  $\geq 15$  times in the month before the interview [11].

Analyses were performed using NHANES III sample weights and considering the complex survey design. Because NHANES III population estimates derived from 1990, US Census estimates were only available for non-Hispanic White, non-Hispanic Black, and Mexican-American race ethnicity groups; persons belonging to other racial and ethnic groups were combined with non-Hispanic White. Participant characteristics were stratified according to regular aspirin use versus without regular aspirin use. The Student's *t*-test and Wilcoxon signed-rank test were used to assess differences in normally and non-normally distributed continuous variables, respectively. Differences between categorical variables were evaluated through the Chi-square test. The cumulative probability of ASCVD mortality according to aspirin groups was graphed across time for individuals with and without elevated Lp(a). Differences in the cumulative probability of ASCVD mortality between aspirin groups were assessed through bivariable Cox proportional hazards regression modeling. In multivariable Cox proportional hazards regression modeling, the association between regular aspirin use and ASCVD mortality was assessed among individuals *with* and *without* elevated Lp

(a). The median follow-up time was 26 years.

Covariates adjusted for in regression models included age, sex, race/ethnicity (non-Hispanic Black, non-Hispanic White, and Mexican-American), education (post high school versus high school or below), family history of myocardial infarction at age <50 years, current cigarette smoking, body mass index, systolic blood pressure, total cholesterol, HDL-cholesterol, triglycerides, diabetes, estimated glomerular filtration rate, lipid-lowering medication use, and antihypertensive medication use. Diabetes was defined according to self-report or the utilization of glucose-lowering medication. Statistical analyses were performed using SAS 9.4 (Cary, NC).

### 3. Results

Among 2,990 participants meeting study inclusion criteria (representing 73 million people), mean age was 50 years, 9% were non-Hispanic Black people, 53% were female, and 7% reported regular aspirin use (Table 1). Individuals reporting regular aspirin use were older, more likely to be male, and more likely to be of non-Hispanic White race and ethnicity compared to participants without regular

**Table 2**  
Association of regular aspirin use with ASCVD mortality among United States adults aged 40–70 years without clinical ASCVD, stratified by Lp(a).

	Number of ASCVD Deaths (n)	Hazard Ratio (95% CI)	P-Value	P-Interaction <sup>a</sup>
<b>Model 1<sup>b</sup></b>				
Normal Lp(a) (n = 2,378)				
No Regular Aspirin Use (n = 2,208)	153	Ref	–	0.001
Regular Aspirin Use (n = 170)	22	1.01 (0.81, 1.25)	0.96	
Elevated Lp(a) (n = 612)				
No Regular Aspirin Use (n = 565)	53	Ref	–	
Regular Aspirin Use (n = 47)	4	0.48 (0.28, 0.83)	0.01	
<b>Model 2<sup>c</sup></b>				
Normal Lp(a) (n = 2,378)				
No Regular Aspirin Use (n = 2,158)	151	Ref	–	0.004
Regular Aspirin Use (n = 220)	24	0.82 (0.61, 1.10)	0.17	
Elevated Lp(a) (n = 612)				
No Regular Aspirin Use (n = 560)	53	Ref	–	
Regular Aspirin Use (n = 52)	4	0.43 (0.26, 0.72)	0.005	

Sources of Data: Source of Data: National Center for Health Statistics: The Third National Health and Nutrition Examination Survey and Linked Mortality File. All models adjusted for age, sex, race/ethnicity, education, family history of myocardial infarction <50 years old, cigarette smoking, body mass index, systolic blood pressure, total cholesterol, HDL-cholesterol, triglycerides, diabetes, estimated glomerular filtration rate, lipid-lowering medication use, and anti-hypertensive medication use.

<sup>a</sup> p-interaction value refers to Lp(a) (normal versus elevated) x regular aspirin use (yes versus no).

<sup>b</sup> regular aspirin use defined as having taken aspirin  $\geq 30$  times in the previous month.

<sup>c</sup> regular aspirin use defined as having taken aspirin  $\geq 15$  times in the previous month, to account for possible alternate day dosing regimens.

aspirin use. Median Lp(a) values between aspirin groups were similar. Participants with Lp(a)  $\geq 50$  were more likely to be female and of non-Hispanic Black race compared to those with Lp(a)  $< 50$  mg/dL (**Supplemental Table 1**).

In unadjusted models, among individuals with elevated Lp(a), those reporting regular aspirin use had a significantly lower crude cumulative probability of ASCVD mortality (**Fig. 1A-B**) and lower ASCVD mortality rate per 1000 person years versus those without regular aspirin use (**Supplemental Figure 2**). Contrastingly, the cumulative probability of ASCVD was significantly higher for individuals reporting regular versus non-regular aspirin use among persons without elevated Lp(a).

In multivariable modeling, regular aspirin use was significantly associated with a 52% lower risk of ASCVD mortality among individuals with elevated Lp(a) (HR=0.48, 95% CI: 0.28–0.83), but not for those without elevated Lp(a) (HR=1.01, 95% CI: 0.81–1.25; p-interaction=0.001). Similar findings were observed using an alternate day dosing definition for regular aspirin use (**Table 2**).

#### 4. Discussion

Among a nationally representative sample of US adults without

clinical ASCVD, regular aspirin use was independently associated with a 52% lower risk of ASCVD mortality for those with elevated Lp(a) but not those without elevated Lp(a) over a median 26-year follow-up. This is the first study to observe an ASCVD mortality benefit associated with aspirin therapy for primary prevention for individuals with elevated Lp(a).

Given the high prevalence of elevated Lp(a) (approximately 20% across populations), which is predominantly genetically determined [3], these findings may have substantial public health implications for the utilization of aspirin for primary prevention. Our results build on previous propensity-matched results from the Multi-Ethnic Study of Atherosclerosis that observed a 46% lower risk of coronary heart disease events with regular aspirin use for those with Lp(a)  $\geq 50$  mg/dL [6]. Earlier findings have also identified a 45–55% lower risk of index major adverse cardiovascular events for regular aspirin use among individuals carrying the rs3789220 LPA gene variant, but not for non-carriers [4,5].

Certain limitations should be considered. First, NHANES III survey data are subject to healthy volunteer bias and were collected three decades ago, as the current landscape of US demographics and preventive medications (increase in statins, antihypertensive, glucose-lowering medications) has changed. However, there have been no Food and Drug Administration-approved pharmacotherapies for Lp(a) lowering since NHANES III. Therefore, it is unlikely that current lower background ASCVD risk from non-Lp(a) risk lowering therapies would have affected our observed association between aspirin and ASCVD mortality among those with elevated Lp(a). Second, similar to several additional observational cohort studies [12,13], NHANES III utilized a mass-based (mg/dL) assay for quantifying Lp(a), which may be prone to measurement bias at the extremes of Lp(a) values [14]. While both mass (mg/dL) and particle (nmol/L) measurements are acceptable, particle-based measurement is preferred and efforts are ongoing to facilitate laboratory standardization [15]. Information on aspirin use was only collected at study baseline and also self-reported, subject to recall bias and misclassification [16]. In addition, regular aspirin use was not randomized across Lp(a) groups; however, NHANES III participants were taking aspirin therapy without prior knowledge of Lp(a) values. We sought to minimize these limitations by using two different definitions of regular aspirin use and adjusting for a multitude of risk factors, including kidney function, to mitigate residual confounding. Lastly, information on aspirin safety, including major bleeding events, was unavailable and deaths from others causes were not censored. Future net clinical benefit (benefit-harm) analyses involving the interaction of aspirin and Lp(a) with incident ASCVD and major bleeding events are needed.

#### 5. Conclusion

Regular aspirin use was associated with a 52% lower risk of ASCVD mortality among adults without clinical ASCVD who had elevated Lp(a). These findings suggest that measurement of Lp(a) may help identify individuals who benefit from aspirin therapy for primary prevention.

#### Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors have no conflicts of interest to disclose.

#### CRediT authorship contribution statement

**Alexander C. Razavi:** Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing – original draft, Writing – review & editing, Visualization. **LaTonia C. Richardson:** Methodology, Validation, Data curation, Visualization, Writing – review & editing. **Fátima Coronado:** Writing – review & editing, Validation, Supervision,

Project administration. **Omar Dzaye:** Writing – review & editing, Validation, Methodology. **Harpreet S. Bhatia:** Writing – review & editing, Validation, Methodology, Conceptualization. **Anurag Mehta:** Writing – review & editing, Validation, Methodology. **Arshed A. Quyyumi:** Writing – review & editing, Validation, Methodology. **Viola Vaccarino:** Writing – review & editing, Validation, Methodology. **Matthew J. Budoff:** Writing – review & editing, Validation, Methodology. **Khurram Nasir:** Writing – review & editing, Validation, Methodology. **Sotirios Tsimikas:** Writing – review & editing, Validation, Methodology, Conceptualization. **Seamus P. Whelton:** Writing – review & editing, Validation, Methodology. **Michael J. Blaha:** Writing – review & editing, Validation, Methodology. **Roger S. Blumenthal:** Writing – review & editing, Validation, Methodology. **Laurence S. Sperling:** Writing – review & editing, Validation, Supervision, Project administration, Methodology, Investigation, Conceptualization.

### Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.ajpc.2024.100674](https://doi.org/10.1016/j.ajpc.2024.100674).

### References

- [1] Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. *J Am Coll Cardiol* 2019;74:e177–232.
- [2] Cainzos-Achirica M, Miedema MD, McEvoy JW, Al Rifai M, Greenland P, Dardari Z, et al. Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular Disease in 2019: the MESA study (multi-ethnic study of atherosclerosis). *Circulation* 2020;141:1541–53. <https://doi.org/10.1161/CIRCULATIONAHA.119.045010>.
- [3] Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Biol* 2022;42:e48–60. <https://doi.org/10.1161/ATV.000000000000147>.
- [4] Lacaze P, Bakshi A, Riaz M, Polekhina G, Owen A, Bhatia HS, et al. Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes. *J Am Coll Cardiol* 2022;80:1287–98. <https://doi.org/10.1016/j.jacc.2022.07.027>.
- [5] Chasman DI, Shiffman D, Zee RYL, Louie JZ, Luke MM, Rowland CM, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. *Atherosclerosis* 2009;203:371–6. <https://doi.org/10.1016/j.atherosclerosis.2008.07.019>.
- [6] Bhatia HS, Trainor P, Carlisle S, Tsai MY, Criqui MH, DeFilippis A, et al. Aspirin and cardiovascular risk in individuals with elevated Lipoprotein(a): the multi-ethnic study of atherosclerosis. *J Am Heart Assoc* 2024;13:e033562. <https://doi.org/10.1161/JAHA.123.033562>.
- [7] Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. *Vital Health Stat* 1994;1:1–407.
- [8] Brandt EJ, Mani A, Spatz ES, Desai NR, Nasir K. Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort. *J Clin Lipidol* 2020;14:695–706. <https://doi.org/10.1016/j.jacl.2020.06.010>.
- [9] 2019 Public-Use Linked Mortality Files. *Natl Cent Heal Stat* 2022. <https://www.cdc.gov/nchs/data-linkage/mortality-public.htm>.
- [10] Gunter E.W., Lewis B.G., Koncickowski S.M. Laboratory procedures used for the third national health and nutrition examination survey (NHANES III), 1988–1994. n.d.
- [11] Rolka DB, Fagot-Campagna A, Narayan KMV. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. *Diabetes Care* 2001;24:197–201. <https://doi.org/10.2337/diacare.24.2.197>.
- [12] Guan W, Cao J, Steffen BT, Post WS, Stein JH, Tattersall MC, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol* 2015;35:996–1001. <https://doi.org/10.1161/ATVBAHA.114.304785>.
- [13] Aronis KN, Zhao Di, Hoogeveen RC, Alonso A, Ballantyne CM, Guallar E, et al. Associations of Lipoprotein(a) levels with incident atrial fibrillation and Ischemic Stroke: the ARIC (Atherosclerosis risk in communities) study. *J Am Heart Assoc* 2017;6. <https://doi.org/10.1161/JAHA.117.007372>.
- [14] Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). *Clin Chem* 1995;41. <https://doi.org/10.1093/clinchem/41.2.246>.
- [15] Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein (a) in clinical practice. *J Clin Lipidol* 2024;1–12. <https://doi.org/10.1016/j.jacl.2024.03.001>.
- [16] Liu EY, Al-Sofiani ME, Yeh HC, Echouffo-Tcheugui JB, Joseph JJ, Kalyani RR. Use of preventive aspirin among older US adults with and without diabetes. *JAMA Netw Open* 2021;4:e2112210. <https://doi.org/10.1001/jamanetworkopen.2021.12210>. –e2112210.